K. Riedel

发表

Effect of Rifampicin and CYP2B6 Genotype on Long‐Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

W. Haefeli, L. Bertilsson, J. Burhenne, 2011, Clinical pharmacology and therapeutics.

Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m)

W. Haefeli, Michael Streit, G. Mikus, 2005, European Journal of Clinical Pharmacology.

Oat gum lowers glucose and insulin after an oral glucose load.

P. Wood, K. Riedel, F. Scott, 1991, The American journal of clinical nutrition.

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients

L. Lindquist, W. Amogne, J. Burhenne, 2011, PloS one.

Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania

L. Lindquist, E. Ngaimisi, S. Mugusi, 2012, PloS one.

Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.

W. Haefeli, J. Burhenne, Dirk Theile, 2013, Biochemical pharmacology.

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients

L. Bertilsson, W. Amogne, J. Burhenne, 2012, The Pharmacogenomics Journal.

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.

W. Haefeli, G. Mikus, J. Burhenne, 2009, British journal of clinical pharmacology.

Fluvoxamine Affects Sildenafil Kinetics and Dynamics

W. Haefeli, J. Burhenne, K. Riedel, 2005, Journal of clinical psychopharmacology.

Reduction of Saquinavir Exposure by Coadministration of Loperamide

W. Haefeli, G. Mikus, J. Burhenne, 2004, Clinical pharmacokinetics.

Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine

O. Müller, R. Schirmer, A. Jahn, 2006, Malaria Journal.

High β‐Glucan Oat Bran and Oat Gum Reduce Postprandial Blood Glucose and Insulin in Subjects With and Without Type 2 Diabetes

P. Wood, K. Riedel, F. Scott, 1994 .

Effect of dose and modification of viscous properties of oat gum on plasma glucose and insulin following an oral glucose load

P. Wood, K. Riedel, F. Scott, 1994, British Journal of Nutrition.

Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring

W. Haefeli, G. Mikus, J. Burhenne, 2011, Therapeutic drug monitoring.

In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6

W. Haefeli, G. Mikus, J. Weiss, 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors.

W. Haefeli, J. Burhenne, J. Weiss, 2002, AIDS.

The Pharmacokinetics of Extended‐Release Formulations of Calcium Antagonists and of Amlodipine in Subjects with Different Gastrointestinal Transit Times

F. Scharpf, R. Yeates, T. Zimmermann, 1999, Journal of clinical pharmacology.

Opposite effects of short‐term and long‐term St John's wort intake on voriconazole pharmacokinetics

W. Haefeli, I. Walter‐Sack, G. Mikus, 2005, Clinical pharmacology and therapeutics.

Induction of feather malformations in chick embryos by cadmium: protection by zinc.

R. Narbaitz, S. Kacew, K. Riedel, 1983, Teratology.

In vitro identification of the cytochrome P450 isozymes involved in the N-demethylation of the active opioid metabolite nortilidine to bisnortilidine

G. Mikus, I. Wustrow, J. Weiss, 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

In vivo uptake of azithromycin in human coronary plaques.

C. Schneider, H. Höpp, T. Zimmermann, 2000, The American journal of cardiology.

Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman.

J. Kuchta, A. Gossmann, H. Seifert, 2006, International journal of antimicrobial agents.

Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole.

G. Mikus, K. Riedel, B. Grün, 2009, British Journal of Clinical Pharmacology.

Undeclared exposure to St. John's Wort in hospitalized patients.

W. Haefeli, I. Walter‐Sack, J. Burhenne, 2004, British journal of clinical pharmacology.

Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg.

W. Haefeli, I. Walter‐Sack, G. Mikus, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Steady-state pharmacokinetics and metabolism of voriconazole in patients.

G. Mikus, J. Burhenne, G. Egerer, 2013, The Journal of antimicrobial chemotherapy.

Induction of Voriconazole Metabolism by Rifampin in a Patient with Acute Myeloid Leukemia: Importance of Interdisciplinary Communication To Prevent Treatment Errors with Complex Medications

G. Mikus, J. Burhenne, G. Egerer, 2007, Antimicrobial Agents and Chemotherapy.

Equivalence of a high-performance liquid chromatographic assay and a bioassay of azithromycin in human serum samples.

T. Zimmermann, K. Riedel, A. Wildfeuer, 1992, Journal of chromatography.

Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria

O. Müller, W. Haefeli, I. Walter‐Sack, 2004, European Journal of Clinical Pharmacology.

High-performance thin-layer chromatographic assay for the routine determination of piroxicam in plasma, urine and tissue.

K. Riedel, H. Laufen, 1983, Journal of chromatography.

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

Gerd Mikus, Walter E Haefeli, W. Haefeli, 2006, Clinical pharmacology and therapeutics.

Long‐Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

W. Haefeli, J. Burhenne, E. Ngaimisi, 2010, Clinical pharmacology and therapeutics.

Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.

Geraldine Rauch, Walter E Haefeli, David Czock, 2013, British journal of clinical pharmacology.

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations

L. Bertilsson, W. Amogne, E. Ngaimisi, 2013, PloS one.

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.

W. Haefeli, A. Worku, L. Lindquist, 2011, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration

W. Haefeli, G. Mikus, T. Weinreich, 2010, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40

Gerd Mikus, Torsten Hoppe-Tichy, W. Haefeli, 2003, Clinical pharmacology and therapeutics.

The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.

G. Mikus, G. Egerer, K. Riedel, 2010, British journal of clinical pharmacology.

Simultaneous determination of hypericin and hyperforin in human plasma with liquid chromatography-tandem mass spectrometry.

W. Haefeli, G. Mikus, J. Burhenne, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Comparative Tolerability of Intravenous Azithromycin, Clarithromycin and Erythromycin in Healthy Volunteers

T. Zimmermann, K. Riedel, A. Wildfeuer, 2001 .

Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy

W. Haefeli, G. Mikus, J. Burhenne, 2011, Clinical pharmacology and therapeutics.

High beta-glucan oat bran and oat gum reduce postprandial blood glucose and insulin in subjects with and without type 2 diabetes.

P. Wood, K. Riedel, F. Scott, 1994, Diabetic medicine : a journal of the British Diabetic Association.

Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers

W. Haefeli, G. Mikus, J. Burhenne, 2004, Clinical pharmacology and therapeutics.

Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.

Gerd Mikus, Walter E Haefeli, W. Haefeli, 2003, British journal of clinical pharmacology.

Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.

W. Haefeli, G. Mikus, J. Weiss, 2014, British journal of clinical pharmacology.

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.

L. Bertilsson, J. Burhenne, E. Ngaimisi, 2014, The Journal of antimicrobial chemotherapy.

Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.

G. Mikus, J. Weiss, K. Riedel, 2012, British journal of clinical pharmacology.

Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan.

W. Haefeli, G. Mikus, J. Burhenne, 2014, International journal of clinical pharmacology and therapeutics.

Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry.

W. Haefeli, G. Mikus, J. Burhenne, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry.

O. Müller, W. Haefeli, I. Walter‐Sack, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults.

W. Haefeli, G. Mikus, J. Burhenne, 2014, International journal of clinical pharmacology and therapeutics.

Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]

O. Müller, A. Jahn, U. Mansmann, 2005, Malaria Journal.

Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso

O. Müller, A. Jahn, U. Mansmann, 2005, Tropical medicine & international health : TM & IH.

Enantioselective gas chromatographic assay with electron-capture detection for amlodipine in biological samples.

F. Scharpf, K. Riedel, H. Laufen, 1994, Journal of chromatography. B, Biomedical applications.

Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry

Gerd Mikus, Walter E Haefeli, W. Haefeli, 2012, Analytical and Bioanalytical Chemistry.

In vitro identification of the cytochrome P450 isozymes involved in the N-demethylation of the active opioid metabolite nortilidine to bisnortilidine

G. Mikus, I. Wustrow, J. Weiss, 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.

G. Mikus, G. Egerer, K. Riedel, 2010, British journal of clinical pharmacology.

Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]

B. Coulibaly, K. Riedel, P. Meissner, 2005, Malaria Journal.